This article is more than 5 years old. Information may no longer be current.

Allergan reports 30.6% increase in net product sales for third quarter 2006

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Allergan Inc. reported third quarter net product sales of $791.7 million, a 30.6% increase over the third quarter 2005, according to a press release.

Excluding product sales related to the company's acquisition of Inamed, pharmaceutical net sales increased 11.5% from the same quarter in the previous year. Allergan reported $0.70 diluted earnings per share compared to $1.12 diluted earnings per share reported for the third quarter of 2005.

For the full year, the company is increasing total product net sales guidance to between $2.975 billion and $3.015 billion. The expected amount of pharmaceutical net sales, including Lumigan (bimatoprost ophthalmic solution) and Botox (botulinum toxin type A), has been increased to between $2.610 billion and $2.620 billion, although expectations for sales of Restasis (cyclosporine ophthalmic emulsion) have been lowered to between $265 million and $275 million, according to the release.

The company's board of directors announced a third quarter dividend of $0.10 per share, payable on Dec. 7 to stockholders of record on Nov. 10.